Human studies in the development of human immunodeficiency virus vaccines

Journal of Infectious Diseases

Volumn 172, Issue 5, 1995, Pages 1175-1183

  Dolin, Raphael ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; INFECTION PREVENTION; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMAL; COMPARATIVE STUDY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV SERONEGATIVITY; HIV-1; HUMAN; NEUTRALIZATION TESTS; PAN TROGLODYTES; PROTEIN PRECURSORS; SAFETY; SUPPORT, U.S. GOV'T, P.H.S.; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 0028804812     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/172.5.1175     Document Type: Article

References (91)

1. Bolognesi DP. Human immunodeficiency virus vaccines. Adv Virus Res 1993;42:103-48
2. Fast PE, Walker MC. Human trials of experimental AIDS vaccines. AIDS 1993;7(suppl l):S147-59
3. Dolin R, Keefer M. Vaccines for HIV-1 infection. In: Mandell G, Bennett Dolin R. eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1994:1294 -305
4. Karzon DT. Preventive vaccines. In: Broder S, Merigan TC Jr, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994:667-92
5. Letvin NL. Vaccines against human immunodeficiency virus—progress and prospects. N Engl J Med 1993;329:1400-5
6. Schultz AM, Hu SL. Primate models for HIV vaccines. AIDS 1993; 7(suppl1):S161 -70
7. Letvin NL. Animal models for AIDS. Immunol Today 1990; 11:322-6
8. Palker TJ, Clark ME, Langlois AJ, et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-6
9. Goudsmil J, Debouck C, Meloen RH, et al. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci USA 1988;85:4478-82
10. Javaherian K, Langlois AJ, McDanal C, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768- 72
11. Broliden PA, Ljunggren K, Hinkula J, et al. A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol 1990;64:936-40
12. Veronese FDM, Rahman R, Kalyanaraman VS, et al. Monoclonal antibodies to IITLV-III451 gp41: delineation of an immunoreactive conserved epitope in the transmembrane region of divergent isolates of HIV-1. AIDS Res Hum Retroviruses 1989;5:479-86
13. Tyler DS, Stanley SD, Zolla-Pazner S, et al. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990; 145:3276-82
14. Birx DL, Redfield RR. Therapeutic HIV vaccines: concept, current status, and future directions. In: Broder S, Merigan TC Jr, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994; 693-711
15. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-35
16. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1992;57:183-9
17. Gadjusek DC, Amyx HE, Gibbs CJ Jr, et al. Transmission experiments with human T-lymphotropic retroviruses and human AIDS tissue. Lancet 1984;1:1415-6
18. Francis DP, Feorino PM, Broderson JR, et al. Infection of chimpanzees with lymphadenopathy associated virus. Lancet 1984;11:1276-7
19. Alter JH, Eichberg JW, Masur H, et al. Transmission of HTLV-TII infection from human plasma to chimpanzees: an animal model for AIDS. Science 1984;226:549-52
20. Berman PW, Gregory TJ, Riddle L, ct al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gpl20 but not gpl60. Nature 1990;345:622-5
21. Girard M, Kieny MP, Pinter A, et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-6
22. Derosiers RC. The simian immunodeficiency viruses. Annu Rev Immunol 1990;8:557-76
23. Derosiers RC, Wyand MS, Kodama T, et al. Vaccine protection againstsimian immunodeficiency virus infection. Proc Natl Acad Sci USA 1989;86:6353-7
24. Murphey-Corb M, Martin LN, Davison-Fairburn B, et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989;246:1293-7
25. Murphey-Corb M, Montelaro RC, Miller MA, et al. Efficacy of SiV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. AIDS 1991;5:655-62
26. Gardner MB. Vaccination against SIV infection and disease. AIDS Res Hum Retroviruses 1990;6:835-45
27. Stott EJ. Preliminary report: protection of cynomolgus macaques againstsimian immunodeficiency virus by fixed infected-cell vaccine. Lancet 1990;336:1538-41
28. Stott EJ. Anti-cell antibody in macaques [letter]. Nature 1991;353:393
29. Schulz A, Hu SL. Primate models for HIV vaccines. In: AIDS 1993; a year in review. London: Current Science, 1993;7(suppl 1):S161 -70
30. Daniel MD, Kirchoff F, Czajak SC, et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-41
31. Baba TW, Jeong YS, Penninck D, et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267:1820-5
32. Hoth D, Botognesi DP, Corey L, Vermund SH. HIV vaccine development:progress report. Ann Intern Med 1994;8:603-11
33. Greene WC. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324:308-18
34. Olshevsky U, Helseth E, Furman C, et al. Identification of individual human immunodeficiency virus type 1 gpl20 amino acids important for CD4 receptor binding. J Virol 1990;64:5701-7
35. Javaherian K, Langlois AJ, LaRosa GH, et al. Broadly neutralizing anti bodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990;250:1590-3
36. Ho DD, McKeating JA, Li XL, et al. Conformational epitope on gpl20 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65:489-93
37. Thali M, Olshevsky U, Furman C, et al. Characterization of a discontinuous human immunodeficiency virus type 1 gpl20 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 1991;65:6188-93
38. Montefiori DM, Graham BS, Zhou J, et al. V3 specific neutralizing antibodies in sera from HIV-1 gpl60 - immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gpl20. J Clin Invest 1993;92:840-7
39. Putney SD, McKeating JA. Antigenic variation in HIV. AIDS 1990;4:5120-36
40. Cochran MA, Ericson BL, Knell JD, et al. Use of baculovirus recombinants as a general method for the production of subunit vaccines. In: Ginsburg H, Brown F, Lemer RA, et al., eds. Vaccines 87. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1987:384-8
41. Steimer KS, vanNest G, Dina D, et al. Genetically engineered human immunodeficiency virus envelope glycoprotein gpl20 produced in yeast is the target of neutralizing antibodies. In:Ginsberg H, Brown F, Lemer RA, et al. Vaccines 87. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1987:236-41
42. Haigwood NL, Nara PL, Brooks E, et al. Native, but not denatured recombinant human immunodeficiency virus type 1 gpl20 generates broad-spectrum neutralizing antibodies in baboons. J Virol 1992;66:172-82
43. Lasky LA, Groopman JE, Fennie CW, et al. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986;233:209-12
44. Hart MK, Palker TJ, Matthews TJ, et al. Synthetic peptides containing Tand B cell epitopes from human immunodeficiency virus envelope gpl20 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 1990; 145:2677-85
45. Wang CY, Looney DJ, Li ML, et al. Long-term high titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991;254:285-8
46. Goldstein AL, Naylor PH, Sarin PS, et al. Progress in the development of a pl7-based HIV vaccine: safety and potential efficacy of the HGP-30 synthetic peptide vaccine in humans [abstract MA1342]. In: Program and abstracts: VII International Conference on A1DS/II STD World Congress (Florence, Italy). Rome: Istituto Superiore di Sanita, 1991
47. Adams SE, Dawson KM, Gull K, et al. The expression of hybrid HIV;Tyvims-like particles in yeast. Nature 1987;329:68-70
48. Blick G, Crook S, Buchanan S, et al. A phase I/Tl study of the toxicity, immunogenicity and efficacy of recombinant gpl60 and p24 vaccines (Vax-Syn) in HIV-infected individuals regardless of CD4+ cell count [abstract TuB0562], In: Program and abstracts: VII International Conference on AIDS/III STD World Congress (Amsterdam). Amsterdam: CONGREX Holland, 1992
49. Hu SL, Kosowski SG, Dalrymple JM. Expression of AIDS vims envelope in recombinant vaccinia viruses. Nature 1986;320:537- 9
50. Tartaglia J, Cox WI, Taylor J, et al. Highly attenuated poxvims vectors.AIDS Res Hum Retroviruses 1992;8:1445-7
51. Dolin R, Graham B, Greenberg S, et al. Safety and immunogenicity of an HIV-1 recombinant gpl60 candidate vaccine in humans. Ann Intern Med 1991;114:119-27
52. Belshe RB, Clements ML, Keefer MC, et al. Interpreting serodiagnostic test results in the 1990’s: social risks of HIV vaccine studies in uninfected volunteers. Ann Intern Med 1994;121:584-9
53. Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia vims vaccine expressing HIV envelope glycoprotein. Lancet 1991;337:567-72
54. Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinia-naive adults with human immunodeficiency vims gpl60 recombinant vaccinia vims in a blinded, controlled, randomized clinical trial. J Infect Dis 1992;166:244-52
55. Schwartz D, Gorse G, Clements ML, et al. Induction of HIV-1 neutralizing and syncytium-inhibiting antibodies in seronegative recipients of HIV-1 IIIB rgpl20 subunit vaccines. Lancet 1993;342:69-73
56. Kovacs JA, Vasudevachari MB, Easter M, et al. Induction of humoral and cell-mediated anti-HIV responses in HIV seronegative volunteers by immunization with recombinant gpl60. J Clin Invest 1993;92:919-28
57. Belshe RB, Clements ML, Dolin R, et al. Safety and immunogenicity of a fully glycosylated recombinant gpl60 human immunodeficiency vims type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993;168:1387-95
58. Keefer MC, Graham BS, Belshe RB, et al. Studies of high doses of a human immunodeficiency vims type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1 - seronegative humans. AIDS Res Hum Retroviruses 1994;10:1713-23
59. Keefer MC, Graham BS, McElrath MJ, et al. Phase I trial of an HIV-1vaccine candidate, Env 2-3, in combination with MTP-PE/MF59 [abstract PO-A29-0708]. In: Program and abstracts: IX International Congress of AIDS/VI STD World Congress (Berlin). London: Wellcome Foundation, 1993
60. Walker MC, Fast PE, Graham BS, Dolin R. C onference on AIDS vaccine development 1994. Summary: phase I/II preventive vaccine trials. AIDS Research and Human Retroviruses 1995 (in press)
61. Keefer M, Belshe RB, Graham BS, et al. Safety profile of HIV vaccination.First 1000 volunteers of AIDS vaccine evaluation group. AIDS Res Hum Retroviruses 1994; 10(suppl 2):S139-40
62. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-in sero-negative volunteers immunized with recombinant gpl20 from the MN strain of HIV-1. JAMA 1994;272:475-80
63. Montefiori DC, Lefkowitz LB Jr, Keller RE, et al. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. AIDS 1991;5:413-7
64. DeSantis C, Robbioni P, Longhi R, et al. Cross-reactive response to H1V-1 gpl20 and HLA class 1 heavy chains induced by receipt of HIV-1 derived envelope vaccines. J Infect Dis 1993;168:1396-403
65. Kahn JO, Sinangil F, Baenziger J, et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gpl20 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994;170:1288-91
66. Graham BS, Keefer MC, McElrath MJ, et al. Phase ! trial of native H1V-1 SF-2 rgpl20 candidate vaccine [abstract Po-A29-0692], In: Program and abstracts: IX International Conference on AIDS/VT STD World Congress (Berlin). London: Wellcome Foundation, 1993
67. VanCott TC, Polonis VR, Loomis LD, et al. Differential role of V3-specific antibodies in neutralization of primary versus laboratory-adapted HIV-1 [abstract 1242]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology, 1994
68. Hanson CV. Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res Hum Retroviruses 1994;10:645-8
69. Mascola JR, Weislow O, Snyder S, et al. Neutralizing antibody activity in sera from human immunodeficiency virus type-1 vaccine recipients from the AIDS vaccine clinical trials network. AIDS Res Hum Retroviruses 1994; 10(Suppl 2):S55
70. Keefer MC, Bonnez W, Roberts NJ Jr, et al. Human immunodeficiency virus (HIV-1) gp 160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gpl60 vaccine recipients. J Infect Dis 1991; 163:448-53
71. Gorse GJ, Belshe RB, Newman FK, et al. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gpl60. Vaccine 1992; 10:383-8
72. Orentas RJ, Hildreth JLK, Obah E. Induction of CD4+ cytolytic T cells specific for HIV-infected cells by a gpl60 subunit vaccine. Science 1990;248:1234-7
73. Stanhope PE, Clements ML, Siliciano RF. Human CD4 cytolytic T lymphocyte responses to a human immunodeficiency vims type 3 gpl60 subunit vaccine. J Infect Dis 1993;168:92-100
74. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to HIV envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gpl60 protein. Proc Natl Acad Sci USA 1993;90:1882-6
75. Graham BS, Matthews TJ, Belshe RB, et al. Augmentation of HIV-l neutralizing antibody by priming with gpl60 recombinant vaccinia and boosting with rgpl60. J Infect Dis 1993; 167:533-7
76. Hammond SA, Bollinger RC, Stanhope PE, et al. Comparative clonal analysis of human immunodeficiency vims type 1 (HIV-1) specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HiV-1 vaccines. J Exp Med 1992;176:1531-42
77. El-Daher N, Keefer MC, Reichman RC, et al. Persisting human immunode ficiency virus-! gp 160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J Infect Dis 1993;168:306-13
78. McElrath MJ, Corey L, Clements ML, et al. A phase II HIV prophylactic vaccine trial in seronegative volunteers: expanded safety and immuno-genicity evaluation of two recombinant gpl20 vaccines [abstract 1242], In: Program and abstracts of the 34th fnterscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology, 1994
79. Public Health Service. HIV Infection in vaccine trial volunteers. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1995
80. Chandra PK, Natuk RJ, Mason BB, et al. High-level expression of the envelope glycoprotein of the human immunodeficiency virus type 1 in presence of rev gene using helper-independent adenovirus type 7 recombinants. Virology 1990;175:535-47
81. Stover CK, delaCruz VF, Ruerst TR, et al. New use of BCG for recombinant vaccines. Nature 1991;351:456-60
82. Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-H1V vaccines. Nature 1991;351:479-82
83. Aggarwal A, Sadoff J, Markham P, et al. Induction of cytotoxic T lymphocytes against HIV-2 in mice immunized with recombinant Salmonella typhimurium [abstract MAI036]. In: Program and abstracts: VII International Conference on AIDS/II STD World Congress (Florence, Italy). Rome: Istituto Superiore di Sanita, 1991
84. Evans DJ, McKeating J, Meredith JM, et al. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 1989;339:385-8
85. Burke KL, Almond JW, Evans DJ. Antigen chimeras of poliovirus. Prog Med Virol 1991;38:56-68
86. Hesseiton RM, Mazzara GP, Panicali D, et al. HIV-specific immune response in rabbits immunized with HIV-like particles and recombinant vaccinia virus [abstract MoA0045]. In: Program and abstracts: VIII International Conference on AIDS/III STD World Congress (Amsterdam). Amsterdam: CONGREX Holland, 1992
87. Hill-Perkins MS, Layton GT, Cole JS, et al. Immune responses to HIV-1epitopes present as hybrid Ty-VLPs [abstract PoA2223]. In: Program and abstracts: VIIT International Conference on AIDS/III STD World Congress (Amsterdam). Amsterdam: CONGREX Holland, 1992
88. Von Brunn A, Eberle J, Reichhuber C, et al. The principal neutralizing determinant (V3) of HIV-1 elicits a high HIV-1 specific antibody response upon expression on HBcAg particles [abstract PoA223!l]. In: Program and abstracts: VIII International Conference on AlDS/ltl STD World Congress (Amsterdam). Amsterdam: CONGREX Holland, 1992
89. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection againstinfluenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9
90. Rhodes GH, Dwarki VJ, Parker SB, et al. Injection of expression vectors containing antigen genes induce cellular and humoral immunity to the antigen [abstract]. In: Program and abstracts of Advances in AIDS Vaccine Development, National Cooperative Vaccine Development Groups for AIDS, 5th annual meeting (Chantilly, VA). Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1992
91. Wang B, Ugen KE, Srikantan V, et al. Genetic immunization: a novel method for vaccine development against HIV [abstract]. In: Program and abstracts of Advances in AIDS Vaccine Development, National Cooperative Vaccine Development Groups for AIDS, 5th annual meeting (Chantilly, VA). Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1992